Sign in
ACOR Stock Price, Chart, Stats & News
Acorda Therapeutics, Inc.
Save
Acorda Therapeutics, Inc. (ACOR) does not currently pay a dividend.
821,028
Market cap
–
Current P/E
–
Forward P/E
ACOR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 60.86% |
Operating margin | -19.78% |
Pretax margin | -251.65% |
Net margin | -214.95% |
Effective tax rate | 14.58% |
ROA | -214.75% |
ROE | 786.07% |
D/E | -1.21x |
Interest coverage ratio | -0.74x |
ACOR valuation
P/E | – |
P/S | 0.01x |
P/B | -0.01x |
P/CF | -0.06x |
P/FCF | -0.06x |
P/OCF | -0.06x |
PEG | -0.00x |
EV multiple | 0.79x |
About
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients.
Similar securities
Based on sector and market capitalization
Report issue